ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters? Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the closing of its initial public offering of 8,625,000 shares of its common stock, which includes the exercise in full of the underwriters? option to purchase 1,125,000 additional shares of its common stock, at a price to the public of $16.00 per share.? The gross proceeds from the offering were $138.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares were offered by ORIC. The shares began trading on The Nasdaq Global Select Market on April 24, 2020, under the symbol ?ORIC.??

Click to view original post